Until eventually a vaccine is in use among the general populace, all likely adverse occasions with the vaccine will not be recognized, necessitating manufacturers to carry out Phase IV reports for postmarketing surveillance from the vaccine even though it can be applied extensively in the public.This phenomenon was first[when?] mentioned from the